Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Chronic Pruritus of Unknown Origin (CPUO)
NCT05263206Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Feb 2022
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of dupilumab in chronic pruritus of unknown origin (CPUO), sponsored by Sanofi. Started Feb 2022; status: recruiting.
02
Drugs
03
Conditions
chronic pruritus of unknown origin (CPUO)
Beyond the preview
Go deeper on NCT05263206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05263206.